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Summary
Objective: To investigate possible underlying mechanisms for alterations in lamo-
trigine (LTG) kinetics by gestation and use of contraceptives.
Methods: Plasma concentrations of LTG and its main metabolite lamotrigine-2-N-
glucuronide (2-N-GLUC) were measured in 31 women on LTG taking combined oral
contraceptives (COC), in 12 with contraceptive intrauterine devices containing
levonorgestrel (CIUD), and in 20 on LTG without hormonal contraception (controls).
We also measured the levels of LTG and 2-N-GLUC in plasma and urine in eight women
during pregnancy, and up to three months postpartum. LTG levels in plasma were
measured by high-performance liquid chromatography method (HPLC) and N-2-GLUC
in urine and plasma and LTG in urine by liquid chromatography—mass spectrometry
(LC/MS).
Results: There were no significant differences in LTG dose/concentration (D/C), or N-
2-GLUC/LTG ratios between women with CIUD and controls. In contrast, compared to
controls, the LTG D/C ratio was 56% higher in women taking COC (mean  SD, 83  47
versus 53.0  24.2; p < 0.01) and N-2-GLUC/LTG ratio 82% higher in women taking
COC (mean 0.477  0.212 SD versus 0.262  0.127; p < 0.0003.
The 2-GLUC/LTG ratios were 154% higher in plasma and 122% higher in urine in late
pregnancy compared with baseline 3 months postpartum.
Conclusions: Our data indicate that the alterations in LTG kinetics in pregnancy as
well as those induced by COC are mainly explained by enzymatic induction of the N-2-
glucuronide pathway. In addition we found no evidence for an interaction between
LTG and CIUD.
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Lamotrigine (LTG) has become the most widely used
among newer antiepileptic drugs (AED) in women
with epilepsy that are of reproductive age.
LTG is metabolized via glucuronidation by uridin-
diphosphate glucuronosyltransferase (UGT), and is
mainly formed to an inactive 2-N-glucuronide (2-N-
GLUC) by isoenzyme UGT1A4.1 Three additional
minor metabolites, lamotrigine-2-N-methyl, lamo-
trigine-2-N-oxide, and lamotrigine-5-N-glucuronide
have been proposed, but there is no conclusive
evidence of their presence in humans.2
LTG plasma concentrations are substantially
lower during comedication with combined oral con-
traceptives (COC), compared with when LTG is
taken alone.3—6 Several studies have also revealed
marked alterations in LTG kinetics during pregnancy
with a significant increase in the apparent clear-
ance.7—12 Induction of glucuronidation by hormonal
factors has been proposed as the mechanism, and
two recent reports provide some support for this
hypothesis based on measurements of LTG metabo-
lites in plasma during pregnancy and in urine in
conjunction with use of COC.6,13
The aim of this study was to advance our under-
standing of the role of induction of the 2-N-GLUC
pathway for the effects of pregnancy and hormonal
contraception on LTG disposition by extending our
previous series of pregnant women as well as study
women on different types of contraception and by
measuring metabolites in plasma as well as urine.Patients and methods
Contraception
Women between 15 and 45 years of age, who were
on LTG in monotherapy or in combination therapyTable 1 Characteristics of women treated with lamotrigine
known to interact with lamotrigine) during pregnancy
Patient
number
Age during
delivery (years)
Lamot
at base
1a 35 500
2a 32 300
3a 32 400
4a 32 200
5a 32 400
6 35 100
7 26 300
8 35 400
a Plasma concentration data have been reported for these patien
b From gestational week 26 co-medication with topiramate.with drugs not known to affect LTG kinetics, were
asked to participate. Blood samples were collected
immediately before the morning dose (trough con-
centration) at steady-state and concentrations of
LTG and its main metabolite 2-N-GLUC were mea-
sured in plasma. Thirty-one women were taking LTG
in combination with COC, 12 women were using
intrauterine contraception containing levonorges-
trel (CIUD), and 20 women on LTG monotherapy
but without hormonal contraception served as con-
trols (the same controls have been used in a previous
publication13). The LTG dose/plasma concentration
(C/D) and 2-GLUC/LTG ratios were determined and
compared between the three groups.
Pregnancy
Eight women on LTG in monotherapy (or with come-
dication known not to interact with LTG) were
included. Their characteristics are summarised in
Table 1. Blood samples for determination of LTG and
2-N-GLUC were obtained before the morning dose
once each trimester and at baseline up to three
months after delivery. In addition, 24 h urine collec-
tions were obtained on the same occasions for
determination of LTG and 2-N-GLUC. Ratios of 2-
GLUC/LTGwere determined in plasma and urine and
compared between the different stages of preg-
nancy and postpartum.
Drug analytical method
LTG concentrations in plasmawere determined by an
established routine high-performance liquid chroma-
tography method (HPLC).14 Using this method, the
range of quantification for LTG is 2—100 mmol/L with
a coefficient of variation (CV) for LTG of less than 8%.
The limit of detection is 0.2 mmol/L.
Plasma concentrations of 2-N-GLUC were mea-
sured by a newly developed method based on liquidmonotherapy (or without concomitant use of other drugs
rigine dose
line (mg/day)
Concomitant antiepileptic
drugs (mg/day)
Topiramateb (150)
None
None
None
Clonazepam (1)
None
None
None
ts in a previous publication.13
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Figure 2 Lamotrigine 2-N-glucuronide/lamotrigine
plasma concentration ratios in 20 non users of oral contra-
ceptives (controls), 12 users of intrauterine contraception
devices containing progestin (CIUD), and 31 users of com-
bined oral contraceptives (COC).chromatography—mass spectrometry (LC/MS).2 The
range of quantification is 0.2 to 50 mmol/L with a CV
less than 16%. The limit of detection is 0.05 mmol/L.
LTG and N-2-glucuronide in urine were analyzed by
using a modification of the LC/MS method developed
for analysis of LTG and N-2-GLUC in plasma.2 The
measuring range of LTG and N-2-glucuronide in urine
was 3—500 mmol/L. The coefficient of variation on
urinewas<5% for LTG and<16% forN-2-glucuronide.
Statistical analysis
The statistical analysis was performed using a Sta-
tistic Software version 7.0 (StatSoft Scandinavia AB,
Uppsala, Sweden). Statistical comparison was con-
ducted using t-test; p-values<0.05 were considered
significant.
The study was approved by the Local Ethics Com-
mittees and all women gave their informed consent.Results
Contraception
The LTG dose was 279  156 mg/day (mean  SD)
among women taking COC compared with 262
 148 mg/day in controls (NS). COC users had 56%
higher D/C than control women (mean  SD,
83  47 L/day versus 53.0  24.2 L/day; p < 0.01)
(Fig. 1) and the N-2-GLUC/LTG ratio was 82% higher
in women taking COC compared with controls (mean
0.477  0.212 SD versus 0.262  0.127; p < 0.0003)
(Fig. 2). There were no statistically significant dif-
ferences in D/C, or N-2-GLUC/LTG ratios between
controls and women with CIUD (Figs. 1 and 2).Figure 1 Dose/lamotrigine plasma concentration ratios
in 20 non-users of oral contraceptives (controls), 12 users
of intrauterine contraception devices containing proges-
tin (CIUD), and 31 users of combined oral contraceptives
(COC).Pregnancy
The mean 2-N-GLUC/LTG ratio in plasma was 154%
higher in late pregnancy than three months post-
partum (mean 1.02  0.271 SD, versus 0.40  0.06;
p < 0.01) (Fig. 3) and 122% higher in urine (mean
46.6  17.2 SD, versus 21.0  5.35; p < 0.01)
(Fig. 4).Discussion
The results of this study confirm earlier reports on
the significant effect of COC on LTG disposition.3—6
We also demonstrate that intrauterine levonorges-
trel contraceptives seem to have no effect on LTG
kinetics, which is in line with a previous report
suggesting that progesterone only oral contracep-
tives do not seem to interact with LTG.15Figure 3 Lamotrigine 2-N-glucuronide/lamotrigine
plasma concentration ratio at different stages of preg-
nancy and up to three months postpartum in eight women
treated with lamotrigine during pregnancy.
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Figure 4 Lamotrigine 2-N-glucuronide/lamotrigine
urine concentration ratio at different stages of pregnancy
and up to three months postpartum in eight women
treated with lamotrigine during pregnancy.Our data, showing a markedly increased 2-N-
GLUC/LTG ratio in plasma in women taking COC,
strongly suggest that this interaction is to a large
extent explained by an induction of UGT1A4, the
isoenzyme responsible for the metabolism of LTG to
2-N-GLUC. Our findings are further supported by a
placebo-controlled trial where the 2-N-GLUC/LTG
ratio in urine decreased by30% (NS) when COC was
replaced by placebo.6
The present study furthermore suggests that
similar mechanisms may explain the marked decline
in LTG plasma concentrations during pregnancy.7—12
We found in late pregnancy a 154% increase in the 2-
N-GLUC/LTG ratio in plasma and 122% in urine com-
pared with three months post partum. The changes
in 2-N-GLUC/LTG ratios seen in plasma over the
course of the pregnancy are closely mirrored by
similar changes in urine.
In conclusion, our data show that the alterations
of the pharmacokinetics in LTG in pregnancy as well
as those induced by COC are mainly caused by
enzymatic induction of the N-2-glucuronide path-
way and suggest that similar hormonal factors may
be instrumental in both situations.Acknowledgement
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